Related Experiment Videos
IL-18 binding protein protects against contact hypersensitivity.
Thomas Plitz1, Pierre Saint-Mézard, Masataka Satho
1Department of Immunology, Serono Pharmaceutical Research Institute, Geneva, Switzerland. Thomas.Plitz@serono.com
Journal of Immunology (Baltimore, Md. : 1950)
|July 23, 2003
Summary
Interleukin-18 binding protein (IL-18BP) effectively reduced skin inflammation and T cell accumulation in a mouse model of allergic contact dermatitis. This suggests IL-18BP is a promising therapeutic candidate for treating this common skin disorder.
Area of Science:
- Immunology
- Dermatology
- Inflammation Research
Background:
- Allergic contact dermatitis is a prevalent skin condition caused by repeated exposure to allergens.
- Contact hypersensitivity is the underlying immune mechanism driving allergic contact dermatitis.
- Interleukin-18 (IL-18) is implicated in inflammatory skin conditions.
Purpose of the Study:
- To investigate the therapeutic potential of IL-18 binding protein (IL-18BP) in a murine model of contact hypersensitivity.
- To determine if IL-18BP can mitigate clinical symptoms and prevent disease relapse in contact hypersensitivity.
Main Methods:
- Utilized a murine model to induce allergic contact dermatitis.
- Administered IL-18 binding protein (IL-18BP) to neutralize IL-18 activity.
- Assessed clinical symptoms, T cell infiltration, and local cytokine production (IFN-gamma).
Main Results:
- IL-18BP significantly reduced clinical symptoms of contact hypersensitivity in mice.
- IL-18BP treatment alleviated disease relapses upon re-exposure.
- IL-18BP decreased T cell homing to inflamed skin sites and reduced IFN-gamma production, without affecting edema.
Conclusions:
- IL-18BP acts as a potent mediator against skin inflammation in contact hypersensitivity by limiting effector T cell accumulation.
- IL-18BP demonstrates therapeutic potential for treating allergic contact dermatitis, supported by IL-18's presence in human disease tissues.